HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $166,170 | +5.9% | 4,350 | 0.0% | 0.01% | +12.5% |
| Q2 2023 | $156,905 | -5.6% | 4,350 | 0.0% | 0.01% | -20.0% |
| Q1 2023 | $166,127 | -35.8% | 4,350 | -4.4% | 0.01% | -37.5% |
| Q4 2022 | $258,895 | +66.0% | 4,550 | +15.2% | 0.02% | +45.5% |
| Q3 2022 | $156,000 | -74.8% | 3,950 | -71.6% | 0.01% | -64.5% |
| Q2 2022 | $618,000 | +8.4% | 13,900 | -2.8% | 0.03% | +29.2% |
| Q1 2022 | $570,000 | -2.2% | 14,300 | -1.4% | 0.02% | +9.1% |
| Q4 2021 | $583,000 | -4.0% | 14,500 | -2.7% | 0.02% | -4.3% |
| Q3 2021 | $607,000 | -13.7% | 14,900 | -1.7% | 0.02% | -14.8% |
| Q2 2021 | $703,000 | -13.1% | 15,150 | -6.5% | 0.03% | +17.4% |
| Q1 2021 | $809,000 | +20.7% | 16,210 | +0.1% | 0.02% | -14.8% |
| Q4 2020 | $670,000 | +24.1% | 16,200 | -21.9% | 0.03% | -3.6% |
| Q3 2020 | $540,000 | -5.1% | 20,750 | -9.8% | 0.03% | -12.5% |
| Q2 2020 | $569,000 | +38.4% | 23,000 | -2.1% | 0.03% | +14.3% |
| Q1 2020 | $411,000 | -6.2% | 23,500 | -3.7% | 0.03% | +21.7% |
| Q4 2019 | $438,000 | +11.7% | 24,400 | -5.4% | 0.02% | 0.0% |
| Q3 2019 | $392,000 | -13.1% | 25,800 | -1.9% | 0.02% | -17.9% |
| Q2 2019 | $451,000 | +4.2% | 26,300 | -2.2% | 0.03% | -3.4% |
| Q1 2019 | $433,000 | +8.8% | 26,900 | -3.6% | 0.03% | 0.0% |
| Q4 2018 | $398,000 | -21.3% | 27,900 | 0.0% | 0.03% | -14.7% |
| Q3 2018 | $506,000 | +7.7% | 27,900 | 0.0% | 0.03% | -8.1% |
| Q2 2018 | $470,000 | -14.9% | 27,900 | -1.1% | 0.04% | -22.9% |
| Q1 2018 | $552,000 | -4.3% | 28,200 | -1.1% | 0.05% | -7.7% |
| Q4 2017 | $577,000 | +15.4% | 28,500 | -1.0% | 0.05% | +4.0% |
| Q3 2017 | $500,000 | +35.5% | 28,800 | 0.0% | 0.05% | +31.6% |
| Q2 2017 | $369,000 | -5.9% | 28,800 | -5.0% | 0.04% | -7.3% |
| Q1 2017 | $392,000 | +34.7% | 30,300 | +2.7% | 0.04% | +7.9% |
| Q4 2016 | $291,000 | -12.9% | 29,500 | +6.5% | 0.04% | -15.6% |
| Q3 2016 | $334,000 | +33.1% | 27,700 | +0.7% | 0.04% | +25.0% |
| Q2 2016 | $251,000 | -3.8% | 27,500 | +2.6% | 0.04% | -10.0% |
| Q1 2016 | $261,000 | – | 26,800 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |